Adaptive Phage Therapeutics receives $9.8 Million in DoD Funding
In most recent news, Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company, announced that the Department of Defense (DoD) has awarded them $9.8 million for the research development of multiple Phase-1 high-priority, bacteriophage-based vaccine candidates against SARS-CoV-2. APT research contract with the DoD will only advance their efforts to deliver a safe and effective phage-vaccine. Recent data has shown that immunity to coronavirus Is not definite, possibly requiring request booster vaccinations to maintain immunity against the virus.
APT will possibly develop an oral delivery system in form of lozenges.” The potential benefits of a phage-based vaccine include versatility for route of administration (mucosal and intramuscular), including a potential oral lozenge, adaptability to virus mutations, speed of development and cost-effectiveness,” said Greg Merril, CEO and co-founder of APT. If phase 1 trials demonstrate safety and immunogenicity, Adaptive Phage Therapeutics predicts rapid advancement for the vaccine through Phase 3 studies and approval.
Amidst the coronavirus pandemic, iNtRON Bio has developed and successfully manufactured a COVID-19 IgG detection device under their specialized trademark, LiliFTM Diagnostics. The LiliFTM GBN COVID-19 IgG Rapid Kit is a simple quantitative range IgG test honed by it’s rapid, easy-to-use, and accurate capability to detect the presence of COVID-19 antibodies. The test is a lateral flow chromatographic immunoassay for the detection of anti-SARS-CoV-2 IgG antibodies in human whole blood, serum, or plasma yielding results in as little as 10-15 minutes.
it is iNtRON.
if it is iNtRON?